Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –November 30, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers
Listing markets:
Euronext Paris from
Nasdaq Global Select
Market in the
Website : www.erytech.com
Date |
Total of shares composing |
Total of brut(1) voting |
Total of net(2) voting |
|||
January 31, 2017 | 8 732 648 | 10 410 050 | 10 407 550 | |||
February 28, 2017 | 8 732 648 | 10 395 830 | 10 393 330 | |||
March 31, 2017 | 8 734 698 | 10 351 950 | 10 349 450 | |||
April 19, 2017 | 11 740 648(3) | 13 303 800(3) | 13 301 300(3) | |||
April 30, 2017 | 11 743 148 | 13 303 549 | 13 301 049 | |||
May 31, 2017 | 11 744 148 | 13 304 550 | 13 302 050 | |||
June 30, 2017 | 11 744 448 | 13 298 756 | 13 296 256 | |||
July 31, 2017 | 11 744 448 | 13 300 266 | 13 297 766 | |||
August 31,2017 | 11 744 448 | 13 301 546 | 13 299 046 | |||
September 30, 2017 | 11 745 648 | 13 300 046 | 13 297 546 | |||
October 31, 2017 | 11 754 422 | 13 304 770 | 13 302 270 | |||
November 16, 2017 | 17 934 559(4) | 19 484 907(4) | 19 482 407(4) | |||
November 30, 2017 | 17 935 659(5) | 19 487 512 | 19 485 012 |
(1)Gross voting rights number (or « theoretical » voting
rights) is used as a basis for calculating the crossing of the
threshold. In accordance with article 223-11 of general regulation of
Autorité des Marchés Financiers, this number is calculated on the basis
of all shares carrying the single and double voting rights, including
shares without voting rights.
(2) Without treasury shares
(3)
The number of shares and voting rights raised following the issuance
of 3 000 000 new shares (cf. Note
d’opération Visa n°17-161 available on the Company’s website)
(4)
The numbers of shares and voting rights raised following the issuance
of 5 374 033 new shares on
(5)
The number of shares increased due to issuance of shares consequently
to warrants exercises which a Board of Director will take notice of in
the future.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171211005439/en/
Source:
Erytech Pharma